Oncology Business Management | Specialty

The OncLive Oncology Business Management condition center page is a comprehensive resource for news and expert insights on business-focused updates and topics in oncology practices, including diversity efforts, telehealth, gaps in care, payment models, and more. This page features news articles, interviews in written and video format, and podcasts that focus on updates and best practices with oncology business management.

Nivolumab Before Ipilimumab Has Greater Efficacy, Similar AEs

September 27th 2015

Two strategies of sequential immunotherapy for advanced melanoma showed similar safety and tolerability but substantially different efficacy.

FDA Awards Research Grants for 18 Rare Diseases, Including HPV-Related Oropharyngeal Cancer

September 22nd 2015

Eighteen new research grants, totaling more than $19 million, have been awarded by the FDA for product development in rare diseases such as HPV-related head and neck cancer and recurrent glioblastoma.

FDA Grants Priority Review to Maintenance Ofatumumab in CLL

September 21st 2015

The FDA has granted a priority review designation to ofatumumab as a maintenance therapy for patients with relapsed chronic lymphocytic leukemia following a response to second- or third-line therapy.

FDA Grants Nivolumab Breakthrough Designation in Renal Cell Carcinoma

September 16th 2015

Nivolumab (Opdivo) has received an FDA breakthrough therapy designation for the treatment of patients with advanced renal cell carcinoma.

340B Program Costs Exceed Earlier Estimates

September 15th 2015

Costs under the 340B program have ballooned far beyond earlier estimates, based on certain aspects of the program that have not been looked at closely.

FDA Approval Sought for Frontline Ibrutinib in CLL

September 14th 2015

A supplemental new drug application has been submitted for the BTK inhibitor ibrutinib (Imbruvica) as a therapy for treatment-naive patients with chronic lymphocytic leukemia who are over the age of 65.

Value-Based Care: Why Include Factors Beyond Oncologists' Control?

September 14th 2015

How can any analysis of the quality of cancer care being delivered by providers that focuses on a survival outcome as the ultimate measure of that quality-rather than on an evaluation of the optimization of the care process-be considered objectively valid and clinically meaningful?

FDA-Approved Rolapitant Offers New Option for CINV

September 10th 2015

Marleen Meyers, MD, discusses rolapitant (Varubi), which the FDA recently approved to prevent delayed CINV.

FDA Grants Alectinib Priority Review in NSCLC

September 9th 2015

Alectinib received an FDA priority review designation for patients with ALK-positive, locally advanced or metastatic nonâ€“small cell lung cancer (NSCLC) who have progressed or are intolerant to crizotinib (Xalkori).

FDA Grants Ixazomib Priority Review in Multiple Myeloma

September 9th 2015

The FDA has granted a priority review designation to the oral proteasome inhibitor ixazomib in combination with lenalidomide and dexamethasone as a treatment for patients with relapsed and/or refractory multiple myeloma.

Overregulation May Delay Access to Life-Prolonging Medications, Increase Costs

September 7th 2015

Overregulation of new drug development has driven up the cost of care and resulted in significant loss of human life by delaying the approval of effective medications.

First US Biosimilar Finally Reaches Market

September 3rd 2015

The first FDA-approved biosimilar, Zarxio, is now available for patients in the United States, following a series of lawsuits and court decisions.

FDA Approves Rolapitant for CINV

September 2nd 2015

The FDA has approved rolapitant (Varubi) for use in combination with other antiemetic agents to prevent delayed CINV.

FDA Grants Elotuzumab Priority Review in Multiple Myeloma

September 1st 2015

The FDA has granted elotuzumab (Empliciti) a priority review for use in combination therapy in pretreated patients with multiple myeloma.

Cabozantinib Granted FDA Breakthrough Designation in Renal Cell Carcinoma

August 24th 2015

Cabozantinib (Cometriq) has received a breakthrough therapy designation from the FDA for the treatment of patients with advanced renal cell carcinoma following one prior therapy.

Frontline Pembrolizumab Receives FDA Priority Review in Melanoma

August 18th 2015

The FDA has granted a priority review to pembrolizumab (Keytruda) as a frontline treatment for patients with advanced melanoma.

FDA Delays Decision on Frontline Nivolumab in Melanoma

August 12th 2015

The FDA has extended the review period for frontline nivolumab in patients with advanced melanoma by 3 months, to allow ample time to review additional data submitted by the PD-1 inhibitor's developer Bristol-Myers Squibb.

CMS Standards for Reporting Call for Advanced Technology, Training

August 8th 2015

Many oncology practices have already made progress in adding appropriate personnel and implementing technology solutions, such as EHR, to enhance their ability to document and report care plans and patient event data. However, to be successful in meeting the specific criteria set forth in the OCM, most existing EHRs will need to be enhanced.

Electronic Health Records Can Increase Malpractice Liability

August 6th 2015

It may be too early to say whether EHRs have increased or decreased liability for physicians as a whole, but some say the technology generally reduces total medical errors and has no effect on insurance rates.

Regulatory Filings Move Dabrafenib/Trametinib Combo Closer to Full Melanoma Approval

July 24th 2015

The FDA has assigned a priority review designation to the combination of dabrafenib and trametinib for patients with unresectable or metastatic BRAFV600 mutation-positive melanoma.